efficacy of targeted therapies after pd-1/pd-l1 blockade in metastatic renal cell carcinoma
Published 7 years ago • 176 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
0:42
dr. mcdermott on targeting pd-1 and pd-l1 in kidney cancer
-
1:30
targeted therapies for the treatment of mrcc after nivolumab-ipilimumab failure
-
1:20
renal cell carcinoma: the emulsion and checkmate 214 trials
-
1:17
optimal therapy sequencing in kidney cancer
-
1:36
avelumab and pembrolizumab for the treatment of merkel cell carcinoma
-
4:16
recent advances in metastatic kidney cancer
-
2:53
immunotherapy and targeted therapy for advanced arcc
-
4:15
case review: symptomatic metastatic renal cell cancer
-
1:40
targeted therapies for renal cell carcinoma
-
1:25
managing side effects of cabozantinib treatment for metastatic renal cell carcinoma
-
26:02
systemic targeted therapy for metastatic renal cell carcinoma in 2012 eric jonasch, m.d
-
2:53
immunotherapy and targeted therapy for advanced arcc
-
1:29
what is targeted therapy?
-
1:02
an expert looks to the future of metastatic kidney cancer treatment
-
20:11
cytoreductive surgery in the era of targeted therapy for kidney cancer
-
4:07
case review: metastatic renal cell carcinoma
-
1:08
pd-l1 potential in liver cancer
-
1:34
dr. quinn on combinations of targeted therapy in rcc
-
28:46
targeted therapies for the treatment of kidney cancer, eric jonasch, md